Silexion Therapeutics
SLXN
8 hedge funds and large institutions have $258K invested in Silexion Therapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
60% more funds holding
Funds holding: 5 → 8 (+3)
0.01% more ownership
Funds ownership: 0.02% → 0.02% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $260K → $258K (-$1.72K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$32.8K |
| 2 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
+$18K |
| 3 |
VF
Virtu Financial
New York
|
+$12.9K |
| 4 |
SG
StoneX Group
New York
|
+$10.2K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WCM
1
Wildcat Capital Management
New York
| $91.9K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $88.5K | +$32.8K | +242 | +50% |
|
|
MHC
3
Meyer Handelman Company
Rye Brook,
New York
| $26.7K | – | – | – |
|
|
MSAM
4
Moloney Securities Asset Management
Manchester,
Missouri
| $16.2K | +$18K | +133 | New |
|
|
SS
5
SBI Securities
Tokyo,
Japan
| $13.3K | – | – | – |
|
|
VF
6
Virtu Financial
New York
| $12K | +$12.9K | +95 | New |
|
|
SG
7
StoneX Group
New York
| $9.11K | +$10.2K | +75 | New |
|
8
Bank of America
Charlotte,
North Carolina
| $405 | – | – | – |
|
SLXN Hedge Fund Activity: Q2 2025 in Review
8 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q2 2025, worth a combined $258K — down 0.66% from $260K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SLXN positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $32.8K.
- 8 institutional investors held Silexion Therapeutics (SLXN) as of Q2 2025, up from 5 in Q1 2025.
- Funds reported $258K of Silexion Therapeutics stock for Q2 2025, down 0.66% quarter-over-quarter.
- 3 funds opened new Silexion Therapeutics positions in Q2 2025 and 0 closed out, a net change of +3 holders.
- The largest Silexion Therapeutics buyer in Q2 2025 was UBS Group, an estimated $32.8K added.
Based on aggregated 13F filings for Q2 2025.